AI Summary & Key Takeaways
AI InsightConclusion:HBsAb decreased after CT, especially in acute leukemia and male patients, and in patients receiving intensive CT
📌 3 Key Takeaways
Abstract
To investigate the influence of chemotherapy (CT) on HBsAb titer in patients receiving CT due to hematological malignancy. Materials and Methods:The data of 75 patients who received CT with the diagnosis of various hematological malignancies and who had serum HBsAb levels measured prior to and after the cessation of CT were evaluated retrospectively. Results:The median age of the patients was 52 years with 49 (65%) males and 26 (35%) females. Median HBsAb titer decreased significantly after CT compared to the pre-CT median HBsAb titer [68 vs. 100 ] (p=0.001). In subgroup analysis, median HBsAb titer decreased significantly after CT in acute leukemia patients [110 vs. 67.8 ] (p=0.003) and in patients receiving intensive CT [97.2 vs. 71 ] (p=0.036). The decrease in median HBsAb titer was significant in male patients (p<0.001). HBsAb became negative after CT in 9 patients who were HBcAb-negative and had lower pre-CT HBsAb levels. Conclusion:HBsAb decreased after CT, especially in acute leukemia and male patients, and in patients receiving intensive CT
Özet
Bu çalışmada, hematolojik malignite nedeniyle kemoterapi alan hastalarda kemoterapinin Anti HBs antikor titresi üzerine olan etkisinin incelenmesi amaçlanmıştır.Gereç ve Yöntemler:Çeşitli hematolojik malignite tanısı ile kemoterapi alan ve hem kemoterapi öncesi hem de kemoterapi tamamlandıktan sonraki Anti HBs antikor titresi mevcut olan toplan 75 hasta retrospektif olarak incelendi. Bulgular: Hastaların ortanca yaşı 52 olup 49'u (%65) erkek ve 26'sı (%35) kadın idi. Kemoterapi sonrası ortanca Anti HBs antikor titresinde kemoterapi öncesine göre anlamlı düşme saptandı [68 vs. 100 ] (p=0,001). Alt grup analizi yapıldığında, kemoterapi sonrası ortanca Anti HBs antikor titresindeki azalmanın özellikle akut lösemi hastalarında [110 vs. 67.8 ] (p=0,003) ve yoğun kemoterapi alan hastalarda [97,2 vs. 71 ] (p=0,036) olduğu gözlendi. Ayrıca ortanca Anti HBs antikor titresindeki azalma erkek cinsiyette daha belirgin idi (p<0,001). Kemoterapi öncesi Anti Hbs antikor titresi düşük olan ve yine Anti HBc antikoru negatif olan dokuz hastada kemoterapi sonrası Anti HBs antikoru negatifleşti.Sonuç: Anti HBs antikor titresinde kemoterapi sonrasında azalma görülmüştür ve bu azalma akut lösemi hastalarında, erkek hastalarda ve yoğun kemoterapi alan hastalarda daha belirgin olarak saptanmıştır